The RNA-binding protein LARP1 is a post-transcriptional regulator of survival and tumorigenesis in ovarian cancer

RNA-binding proteins (RBPs) are increasingly identified as post-transcriptional drivers of cancer progression. The RBP LARP1 is an mRNA stability regulator, and elevated expression of the protein in hepatocellular and lung cancers is correlated with adverse prognosis. LARP1 associates with an mRNA interactome that is enriched for oncogenic transcripts. Here we explore the role of LARP1 in epithelial ovarian cancer, a disease characterized by the rapid acquisition of resistance to chemotherapy through the induction of pro-survival signalling. We show, using ovarian cell lines and xenografts, that LARP1 is required for cancer cell survival and chemotherapy resistance. LARP1 promotes tumour formation in vivo and maintains cancer stem cell-like populations. Using transcriptomic analysis following LARP1 knockdown, cross-referenced against the LARP1 interactome, we identify BCL2 and BIK as LARP1 mRNA targets. We demonstrate that, through an interaction with the 3′ untranslated regions (3′ UTRs) of BCL2 and BIK, LARP1 stabilizes BCL2 but destabilizes BIK with the net effect of resisting apoptosis. Together, our data indicate that by differentially regulating the stability of a selection of mRNAs, LARP1 promotes ovarian cancer progression and chemotherapy resistance.

[1]  C. Chaparro,et al.  XRN4 and LARP1 are required for a heat-triggered mRNA decay pathway involved in plant acclimation and survival during thermal stress. , 2013, Cell reports.

[2]  Eric S. Lander,et al.  Identification of Selective Inhibitors of Cancer Stem Cells by High-Throughput Screening , 2009, Cell.

[3]  C. Gissi,et al.  Untranslated regions of mRNAs , 2002, Genome Biology.

[4]  N. Dubrawsky.  Cancer statistics , 1989, CA: a cancer journal for clinicians.

[5]  A. Jemal,et al.  Cancer statistics, 2013 , 2013, CA: a cancer journal for clinicians.

[6]  I. Weissman,et al.  Overexpression of BCL2 enhances survival of human embryonic stem cells during stress and obviates the requirement for serum factors , 2011, Proceedings of the National Academy of Sciences.

[7]  T. Sengupta,et al.  Mechanism of Regulation of bcl-2 mRNA by Nucleolin and A+U-rich Element-binding Factor 1 (AUF1)* , 2010, The Journal of Biological Chemistry.

[8]  Robert C. Bast,et al.  The biology of ovarian cancer: new opportunities for translation , 2009, Nature Reviews Cancer.

[9]  P. Anderson,et al.  Post‐transcriptional regulation of proinflammatory proteins , 2004, Journal of leukocyte biology.

[10]  A E Willis,et al.  LARP1 post-transcriptionally regulates mTOR and contributes to cancer progression , 2014, Oncogene.

[11]  Andrea J. Berman,et al.  The La-related protein 1-specific domain repurposes HEAT-like repeats to directly bind a 5′TOP sequence , 2015, Nucleic acids research.

[12]  Edward L Huttlin,et al.  Proteomic analysis of cap-dependent translation identifies LARP1 as a key regulator of 5′TOP mRNA translation , 2014, Genes & development.

[13]  Gordon B Mills,et al.  HDAC4-regulated STAT1 activation mediates platinum resistance in ovarian cancer. , 2011, Cancer research.

[14]  Liang Peng,et al.  LARP1 predict the prognosis for early-stage and AFP-normal hepatocellular carcinoma , 2013, Journal of Translational Medicine.

[15]  Y. Totsuka,et al.  HuR keeps an angiogenic switch on by stabilising mRNA of VEGF and COX-2 in tumour endothelium , 2011, British Journal of Cancer.

[16]  Tsuyoshi Saito,et al.  Ovarian Cancer Stem Cells Are Enriched in Side Population and Aldehyde Dehydrogenase Bright Overlapping Population , 2013, PloS one.

[17]  Z. Szallasi,et al.  Implementing an online tool for genome-wide validation of survival-associated biomarkers in ovarian-cancer using microarray data from 1287 patients. , 2012, Endocrine-related cancer.

[18]  S. Blagden,et al.  The La-Related Proteins, a Family with Connections to Cancer , 2015, Biomolecules.

[19]  M. Jedryka,et al.  Evaluation of clinical significance of TP53, BCL-2, BAX and MEK1 expression in 229 ovarian carcinomas treated with platinum-based regimen , 2003, British Journal of Cancer.

[20]  Gen Sheng Wu,et al.  Involvement of MKP-1 and Bcl-2 in acquired cisplatin resistance in ovarian cancer cells , 2009, Cell cycle.

[21]  N. Sonenberg,et al.  The mRNA 5' cap-binding protein, eIF-4E, cooperates with v-myc or E1A in the transformation of primary rodent fibroblasts , 1992, Molecular and cellular biology.

[22]  M. Banerjee,et al.  Expression of aldehyde dehydrogenase and CD133 defines ovarian cancer stem cells , 2012, International journal of cancer.

[23]  C. Lengerke,et al.  SOX2 expression associates with stem cell state in human ovarian carcinoma. , 2013, Cancer research.

[24]  L. Boxer,et al.  A-Myb Up-regulates Bcl-2 through a Cdx Binding Site in t(14;18) Lymphoma Cells* , 2000, The Journal of Biological Chemistry.

[25]  Tom H. Pringle,et al.  The human genome browser at UCSC. , 2002, Genome research.

[26]  G. Kozlov,et al.  La-Related Protein 4 Binds Poly(A), Interacts with the Poly(A)-Binding Protein MLLE Domain via a Variant PAM2w Motif, and Can Promote mRNA Stability , 2010, Molecular and Cellular Biology.

[27]  S. Nelson,et al.  Molecular properties of CD133+ glioblastoma stem cells derived from treatment-refractory recurrent brain tumors , 2009, Journal of Neuro-Oncology.

[28]  R. Hazan,et al.  Correction: Exploiting MEK Inhibitor-Mediated Activation of ERα for Therapeutic Intervention in ER-Positive Ovarian Carcinoma , 2016, PloS one.

[29]  K. Nykamp,et al.  C. elegans La-related protein, LARP-1, localizes to germline P bodies and attenuates Ras-MAPK signaling during oogenesis. , 2008, RNA.

[30]  A. Balmain,et al.  Guidelines for the welfare and use of animals in cancer research , 2010, British Journal of Cancer.

[31]  Ming Jiang,et al.  Bcl-2 constitutively suppresses p53-dependent apoptosis in colorectal cancer cells. , 2003, Genes & development.

[32]  Jordan M. Komisarow,et al.  RIP-Chip: the isolation and identification of mRNAs, microRNAs and protein components of ribonucleoprotein complexes from cell extracts , 2006, Nature Protocols.

[33]  A. Jemal,et al.  Global cancer statistics , 2011, CA: a cancer journal for clinicians.

[34]  Masahiro Morita,et al.  La-related Protein 1 (LARP1) Represses Terminal Oligopyrimidine (TOP) mRNA Translation Downstream of mTOR Complex 1 (mTORC1)* , 2015, The Journal of Biological Chemistry.

[35]  Siu-Ming Yiu,et al.  SOAP2: an improved ultrafast tool for short read alignment , 2009, Bioinform..

[36]  M. Selbach,et al.  Corrigendum: Global quantification of mammalian gene expression control , 2013, Nature.

[37]  G. Rustin,et al.  A multicenter, randomized trial of flat dosing versus intrapatient dose escalation of single-agent carboplatin as first-line chemotherapy for advanced ovarian cancer: an SGCTG (SCOTROC 4) and ANZGOG study on behalf of GCIG. , 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

[38]  Lilya V. Matyunina,et al.  Gene expression profiling supports the hypothesis that human ovarian surface epithelia are multipotent and capable of serving as ovarian cancer initiating cells , 2009, BMC Medical Genomics.

[39]  H. Will,et al.  The RNA-binding protein La contributes to cell proliferation and CCND1 expression , 2011, Oncogene.

[40]  Alexei A. Sharov,et al.  Database for mRNA Half-Life of 19 977 Genes Obtained by DNA Microarray Analysis of Pluripotent and Differentiating Mouse Embryonic Stem Cells , 2008, DNA research : an international journal for rapid publication of reports on genes and genomes.

[41]  Laurence Wurth,et al.  Versatility of RNA-Binding Proteins in Cancer , 2012, Comparative and functional genomics.

[42]  Laurent Ozbun,et al.  A gene signature predicting for survival in suboptimally debulked patients with ovarian cancer. , 2008, Cancer research.

[43]  E. Petricoin,et al.  The mRNA-binding protein HuR promotes hypoxia-induced chemoresistance through posttranscriptional regulation of the proto-oncogene PIM1 in pancreatic cancer cells , 2016, Oncogene.

[44]  Z. Szallasi,et al.  An online survival analysis tool to rapidly assess the effect of 22,277 genes on breast cancer prognosis using microarray data of 1,809 patients , 2010, Breast Cancer Research and Treatment.

[45]  Kathleen R. Cho,et al.  Fibroblast growth factor 9 has oncogenic activity and is a downstream target of Wnt signaling in ovarian endometrioid adenocarcinomas. , 2006, Cancer research.

[46]  K. Kohn,et al.  CellMiner: a web-based suite of genomic and pharmacologic tools to explore transcript and drug patterns in the NCI-60 cell line set. , 2012, Cancer research.

[47]  B. Neville,et al.  Implication of RNA-Binding Protein La in Proliferation, Migration and Invasion of Lymph Node-Metastasized Hypopharyngeal SCC Cells , 2011, PloS one.

[48]  M. Sadelain,et al.  Abstract 3499: CD56 targeted chimeric antigen receptors for immunotherapy of multiple myeloma , 2012 .

[49]  H. Gabra,et al.  The RNA binding protein Larp1 regulates cell division, apoptosis and cell migration , 2010, Nucleic acids research.

[50]  I. Nagata,et al.  Bcl-2 as a predictor of chemosensitivity and prognosis in primary epithelial ovarian cancer. , 1999, European journal of cancer.

[51]  Benjamin J. Raphael,et al.  Integrated Genomic Analyses of Ovarian Carcinoma , 2011, Nature.

[52]  M. Gorospe,et al.  HuR Uses AUF1 as a Cofactor To Promote p16INK4 mRNA Decay , 2010, Molecular and Cellular Biology.

[53]  B. Williams,et al.  Mapping and quantifying mammalian transcriptomes by RNA-Seq , 2008, Nature Methods.

[54]  K. Al-Kuraya,et al.  Abstract 4412: Prognostic significance of NF-κB in Middle Eastern diffuse large B cell lymphoma and efficacy of NF-κB inhibition as a viable therapeutic target , 2011 .

[55]  John M. Ashton,et al.  BCL-2 inhibition targets oxidative phosphorylation and selectively eradicates quiescent human leukemia stem cells. , 2013, Cell stem cell.

[56]  B. Rosen,et al.  Gene Expression Profiles of Luteal Phase Fallopian Tube Epithelium from BRCA Mutation Carriers Resemble High-Grade Serous Carcinoma , 2008, Clinical Cancer Research.

[57]  F. V. Van Dolah,et al.  Global Analysis of mRNA Half-Lives and de novo Transcription in a Dinoflagellate, Karenia brevis , 2013, PloS one.

[58]  Sean J Morrison,et al.  Cancer stem cells: impact, heterogeneity, and uncertainty. , 2012, Cancer cell.

[59]  Hideo Kusano,et al.  LARP1 specifically recognizes the 3′ terminus of poly(A) mRNA , 2013, FEBS letters.

[60]  M. Caligiuri,et al.  BCR/ABL activates mdm2 mRNA translation via the La antigen. , 2003, Cancer cell.

[61]  Jeroen Krijgsveld,et al.  The RNA-binding protein repertoire of embryonic stem cells , 2013, Nature Structural &Molecular Biology.

[62]  R. Agarwal,et al.  Ovarian cancer: strategies for overcoming resistance to chemotherapy , 2003, Nature Reviews Cancer.

[63]  G. Enikolopov,et al.  Ovarian surface epithelium at the junction area contains cancer-prone stem cell niche , 2013, Nature.

[64]  J. Deragon,et al.  A comprehensive analysis of the La-motif protein superfamily. , 2009, RNA.